A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes
© Bucher et al; licensee BioMed Central Ltd. 2011
Received: 25 October 2010
Accepted: 6 May 2011
Published: 6 May 2011
The individual character of pharmacokinetics is of great importance in the risk assessment of new drug leads in pharmacological research. Amongst others, it is severely influenced by the properties and inter-individual variability of the enzymes and transporters of the drug detoxification system of the liver. Predicting individual drug biotransformation capacity requires quantitative and detailed models.
In this contribution we present the de novo deterministic modeling of atorvastatin biotransformation based on comprehensive published knowledge on involved metabolic and transport pathways as well as physicochemical properties. The model was evaluated on primary human hepatocytes and parameter identifiability analysis was performed under multiple experimental constraints. Dynamic simulations of atorvastatin biotransformation considering the inter-individual variability of the two major involved enzymes CYP3A4 and UGT1A3 based on quantitative protein expression data in a large human liver bank (n = 150) highlighted the variability in the individual biotransformation profiles and therefore also points to the individuality of pharmacokinetics.
A dynamic model for the biotransformation of atorvastatin has been developed using quantitative metabolite measurements in primary human hepatocytes. The model comprises kinetics for transport processes and metabolic enzymes as well as population liver expression data allowing us to assess the impact of inter-individual variability of concentrations of key proteins. Application of computational tools for parameter sensitivity analysis enabled us to considerably improve the validity of the model and to create a consistent framework for precise computer-aided simulations in toxicology.
The discovery and development of new drug entities is strongly handicapped by the circumstance that about 50% of the drug candidates fail in the clinical studies . About one quarter of candidate drugs fail due to toxicity or pharmacokinetic (PK) problems , and currently, it is a well known fact, that toxicity is the major cause of attrition in the drug development process . Therefore, it is quite clear that dangerous properties of drug entities have to be revealed very early in the drug evaluation studies . Despite the ever growing effort to apply computational power towards improving the understanding and in-silico prediction of drug pharmacokinetics and response, the overall impact on preclinical safety testing has been modest.
Application of systems biology holds tremendous promise because it aims to understand and quantitatively describe biological phenomena within the framework of the hierarchical levels of metabolic pathways and regulatory networks at the different scales of cells, tissue, organs and ultimately whole organisms [5, 6]. However, despite emerging consensus that such a holistic approach is essential to provide the framework of predictive toxicology, the number of successful case studies is still minuscule [7–9].
Current activities can be grouped into
(1) quantitative structure-activity-relationship (QSAR) methods, computational models based on compound structure and focused on potential interactions of small molecules with major classes of proteins such as drug metabolizing enzymes [10–15], transporters  and receptors [16–18]. Also important are physicochemical properties of the drug, for example solubility and permeability that are estimated from the molecular structure [19–22].
(2) in vitro kinetics for prediction of in vivo drug clearance using kinetic data from recombinant cytochromes P450 (CYPs), microsomes and hepatocytes (IVIVE: in vitro-in vivo extrapolations) .
(3) physiologically based PK (PBPK) modeling [24–28] which considers the anatomical, physiological and chemical aspects of ADME (absorption, distribution, metabolism and elimination of the drug) [29–31] in multi-compartment models .
In addition to these simulations based on mathematical models various computational and bioinformatics approaches are applied to extract information from high throughput data of drug response experiments at cellular, tissue, organ and whole organism level.
A critical assessment of the aforementioned tools, essentially to outline gaps that must be addressed for more reliable predictive simulation-based toxicology, indicates needs for more rigorous network models focusing at systems dynamics beyond kinetics of individual enzymes, consideration of inter-individual variability and systematic investigations of parameter sensitivity and its impact on model verification, discrimination and reduction, to name a few. The first issue is related to the design of the dynamic models for the drug elimination process in the hepatocyte, which should be based on the integration of membrane transport processes for substrates and products as well as phase I and phase II reactions. These models need to be tightly linked to stimulus (dose)-response experiments.
The issue of model parameterization in the context of modeling in toxicology has been already addressed in 1995 by Andersen et al . In addition to the problem of identifiability, particular attention should be given to correlation between parameters, very common in biological systems.
Yet another question of interest concerns the subtle integration of the enormous inter-subject variability in enzymatic phenotypes into the model. This is of outermost importance for predictions in toxicology and also in clinical pharmacology in order to design optimal treatments for individual patients. Consideration of this variability in phenotype should rest on quantitative proteomics and activity data from human liver tissue or hepatocytes representing a statistically significant portion of the population.
The importance of this issue has been extensively addressed in the review of Rostami-Hodjegan and Tucker  and discussed in the context of IVIVE (in vitro-in vivo extrapolation) approach. Significant progress has been made by this group through a strategy which is based on the simulation of drug disposition in virtual liver populations. The basic idea of this method is to portray the variability into the r max /K M -values estimated from in vitro studies using human liver microsomes, primary or cryopreserved hepatocytes or recombinant expressed enzymes. This is a promising approach; however, improvement of the strategy is imaginable by separation of the two parameters r max and K M (maximal enzymatic rate and enzymatic affinity parameter in Michaelis-Menten- and derived kinetics).
This concept, which is a focus of the present article, is driven by the possibility to incorporate separate information from pharmacokinetics and quantitative proteomics as well as future incorporation of the regulatory network responsible for variation of expression level of the enzymes, transporters and receptors. As model drug we chose atorvastatin (AS), one of the most frequently used 3-hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). Statins thereby reduce cholesterol synthesis and they also stimulate the uptake of LDL-cholesterol from the blood. Although they are relatively safe drugs, the lipid-lowering effect of statins is inadequate in some patients, and unpredictable drug-drug interactions can occur, as well as hepatic and extrahepatic adverse effects including hepatotoxicity, myopathy, and rare but severe rhabdomyolysis.
Some aspects of dynamic modeling of statins have been tackled in previous studies, including the deterministic modeling of transport kinetics [33, 34] and the pharmacokinetic modeling of the clearance mechanisms including consideration of unspecific binding effects . In the latter case, a multi-compartmental model approach has been derived on isolated rat hepatocytes. However, the metabolism of AS inside the liver cell has not been described in details, missing the kinetic description of the different metabolite formations, which thus far precludes the consideration of inter-individual variability, apart from the fact that rat hepatocytes had been investigated.
This study describes a deterministic modeling approach of the dynamic biotransformation and transport processes of AS in human hepatocytes considering both kinetics of transport processes as well as intracellular detoxification processes via Phase I and Phase II enzymes. Attention is given to the detailed enzymatic and chemical reactions, including conversions between the acid and lactone form of AS as well as unspecific binding between metabolites and macromolecules like proteins. The additional integration of quantitative protein data of Phase I and Phase II enzymes enables the dynamic analysis of the underlying inter-individual-variability of expression levels of these enzymes.
Williams Medium E (WME) without phenol-red and without L-glutamine and stabilized L-glutamine were obtained from Pan-Biotech-GmbH (Aidenbach, Germany). Penicillin/Streptomycin and ITS-X were obtained from Invitrogen (Karlsruhe, Germany). Bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich Chemicals (Taufkirchen, Germany). Dexa Inject was obtained from Jenapharm (Jena, Germany). AS, its metabolites and deuterated standards were purchased from Toronto Research Chemicals Inc. (North York, Canada). PBS was obtained from Invitrogen (Karlsruhe, Germany) and Complete Mini, EDTA-free from Roche Diagnostics (Mannheim, Germany). NaPP, sucrose and LiChrosolv were purchased from Merck (Darmstadt, Germany); acetonitrile from Roth (Karlsruhe, Germany), formic acid from Fluka, (Germany), UGT1A3 monoclonal mouse antibody from Abcam (Cambridge, England). Trypsin was purchased from Promega (Mannheim, Germany). Synthetic peptides were purchased from Sigma-Genosys (Haverhill, UK).
Isolation and cultivation of primary human hepatocytes
Tissue samples from human liver resections were obtained from patients undergoing partial hepatectomy. Experimental procedures were performed according to the guidelines of the charitable state-controlled foundation HTCR (Human Tissue and Cell Research) Regensburg, Germany, and the institutional guidelines for liver resections of tumor patients with primary or secondary liver tumors, Technical University Munich, MRI, Munich, Germany. The use of human hepatocytes for research purposes was approved by the local ethics committees of the Ludwig-Maximilians-University of Munich  and the Charité, Humboldt University Berlin , Germany, and written informed consent was obtained from all patients. Hepatocytes were cultured on collagen gel precoated 6-well plates at a density of 1.5·106 cells/well. Cells were allowed to attach to the collagen layer. After transport, culture media was disposed and attached cells were cultured 24 h at 37°C in a humidified chamber with 95%/5% air/CO2 in serum-free medium WME, supplemented with albumin (0.1% (v/v)), penicillin/streptomycin (100 U/ml), stabilized L-glutamine (2 mM), dexamethasone dihydrogenphosphate (0.025% (v/v)) and ITS-X (5 mg insulin, 3.35 μg natrium-selenit, 2.75 mg transferrin and 1 mg ethanolamine), further named SFM.
Incubation with AS was started by disposing the culture media and cultivation of the attached cells at 37°C in a humidified chamber with 95%/5% air/CO2 in 2 ml SFM, supplemented with 10 μM AS, 0.1% (v/v) BSA and 0.1% DMSO. At specified time-points, three wells were further treated for the preparation of samples for the measurement of extracellular and intracellular metabolites, respectively. SFM media was collected and 50 μL formic acid and deuterated internal standard was added for the further measurement of extracellular metabolites. Cells were harvested in pre-cooled albumin-free SFM, disrupted by freeze/thaw and ultra-sonification and centrifuged. The supernatant was used for the determination of intracellular metabolites.
For the preparation of samples for the protein measurements, culture medium was disposed and cells were harvested in pre-cooled PBS, supplemented with Complete Mini EDTA-free (1 Tablet/10 ml Buffer). Cell suspensions were centrifuged 5 min (500 g) at 4°C and cell pellets were resuspended in 150 μL NaPP-buffer (0.1 M, pH 7.4), containing 250 mM sucrose and Complete Mini EDTA-free (1 Tablet/10 ml Buffer). Cells were disrupted by ultra-sonification and lyophilized for the analysis of total protein concentration, CYP3A4 and UGT1A3 content.
For cell number determination, cells from two wells were fixed with methanol-acetic acid fixative solution (10 min at 37°C and 4°C) and afterwards nuclei were stained for 15 min with Meyers Hämalaun (Sigma-Aldrich Chemie GmbH, Germany), rinsed with water and air-dried. Stained nuclei were counted in digital images (10 per well) at 40-fold Magnification (ImageJ Image Processing and Analysis Program).
Quantification of atorvastatin and its metabolites
AS and ASL, and their para- (ASpOH, ASLpOH) and ortho-hydroxy-metabolites (ASoOH, ASLoOH), were determined by LC-MS-MS analysis using the respective deuterium labeled analogues as internal standards, essentially as described . HPLC separation was performed at 30°C on a XBridge Shield RP18 column (2.1 × 50 mm, 3.5 μm, Waters) using (A) 1 mM formic acid and (B) acetonitrile as mobile phases at a flow rate of 0.4 ml/min. Gradients were programmed as follows: 63% A for 4 min; linear decrease of A to 60% within 9 min; linear decrease of A to 55% within 2.5 min; 55% A for 1 min; increase of A to 63% in 0.2 min. Equilibration time of the column was 20 min. MS-MS analysis was performed on an Esquire HCT ultra ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) coupled to an HPLC 1100-System (Agilent, Waldbronn, Germany) consisting of binary pump G1312A, degasser G1379A, well-plate sampler G1367A and column thermostat G1330B. The ionization mode was electrospray (ESI), polarity positive, mass range mode ultrascan, and nitrogen was used as a drying and nebulizer gas. The following parameters were applied: nebulizer 45 psi, dry gas 10 l/min, dry temperature 300°C, capillary 4100 V, scan range 200 - 600 m/z.
Precursor and product ions (m/z) of analytes and internal standards, respectively, were ATV (559 and 440.2; 466.2), [2H5]ATV (564 and 445.2; 471.2), ATV-L (541.2 and 448.2), [2H5]ATV-L (546.2 and 453.2), p-OH-ATV (575 and 440.2; 466.2), [2H5]p-OH-ATV (580 and 445.2; 471.2), p-OH-ATV-L (557 and 448.4), [2H5]p-OH-ATV-L (562 and 448.4), o-OH-ATV (575 and 466.4), [2H5]o-OH-ATV (580 and 471.2), o-OH-ATV-L (557 and 448.4), [2H5]o-OH-ATV-L (562 and 448.4). Sample quantification was possible in a range from 0.5 to 500 pmol.
CYP3A4 and UGT1A3 protein quantification
Protein quantification of CYP3A4 and UGT1A3 in human liver microsomes and relative protein quantification of UGT1A3 in lyophilized samples of primary hepatocytes was performed by immunoblotting as described previously [38, 39].
Cell lysates for absolute quantification analysis of CYP3A4 were prepared from lyophilized human primary hepatocytes by sonification in the presence of glass beads in buffer containing Complete Mini-Protease Inhibitor Cocktail, and following homogenization. In the CYP3A4 quantification assay, three synthetic isotopically labeled peptides (13C/15N amino acid) were used as internal standard for calibration. These isotope labeled standard peptides represented sequence analogues to proteotypic peptides of CYP3A4, which arise from tryptic digestion. After acetone precipitation and resolving of the proteins in 8 M Urea, a definite amount of internal standard peptides was added. The sample mixture was reduced with 5 mM DTT and alkylated with 15 mM iodacetamide in 50 mM ammonium bicarbonate. Subsequently samples were digested with trypsin at 42°C for 4 h (enzyme/substrate ratio of 1:10). Efficiency of tryptic digestion was checked by SDS-PAGE followed by silver staining. The resulting peptides were purified using C18 OMIX® Tips (Varian, Darmstadt, Germany) according to manufacturer's suggested protocol and separated on a nanoliter-flow Ultimate HPLC system (Dionex, Idstein, Germany). After injection (15 μl), peptides were trapped and desalted on a precolumn (0.3 mm I.D. × 5 mm PepMapTM, Dionex) at a flow rate of 30 μl/min in 0.1% TFA for 6 min. Peptides were transferred to the separation column (75 μm I.D. × 250 mm PepMapTM column, Dionex) and separated in a linear gradient of mobile phase (A: 0.1% formic acid, B: 84% acetonitrile/0.1% formic acid) from 5% B to 35% B over a period of 35 min with a flow of 290 nl/min. The column effluent was continuously directed into the NanoSpray II source of a 4000QTrap mass spectrometer (Applied Biosystems, Foster City, CA, USA). The MS was set up to run a multiple reaction monitoring experiment essentially, as described previously , including two to three parent-to-product ion transitions for each internal standard peptide as well as the corresponding transitions of native peptide of CYP3A4. The instrument settings were as follows: ion spray voltage, 3-4 kV; interface heater, 150°C; declustering potential, 50 V; collision energy, peptide specific; entrance potential, 10 V; collision cell exit potential, 10 V. MS data were processed by integrating the appropriate peak areas from extracted ion chromatograms by MultiQuantTM Software (Applied Biosystems). The absolute amount of CYP3A4 protein was calculated from the peak area ratio "internal standard peptide/native peptide". Total protein content of the samples were determined by amino acid analysis (AAA) on a Waters 2695 HPLC system using the AccQ•Tag derivatization method (Waters, Eschborn, Germany), according to manufacturer's instructions.
Identification of metabolic network structure
Numerous metabolic and physicochemical aspects about AS had to be considered in the initial model building. AS exists in two forms, a very lipophilic lactone (ASL) and a comparably hydrophilic hydroxyl-acid (AS). AS is converted enzymatically via an instable intermediate product into ASL, mediated by different UGT isoenzymes [41, 42]. Recent investigations by ourselves and others have shown that the most important contributor to UGT-driven lactonization is UGT1A3, whereas UGT1A1 plays an insignificant role [38, 42]. AS acids and lactones are inter-converted chemically into each other . However, studies have indicated, that the chemical lactonization of AS to ASL can be neglected at physiological pH of 7.4 . Recent studies highlight, that different PON enzymes might also be possible contributors to the lactone hydrolysis and that PON1 is present in liver [44–48].
Both AS and ASL are hydroxylated in human hepatocytes leading to para- and ortho-hydroxy-metabolites, ASpOH, ASoOH, ASLpOH and ASLoOH [49, 50], mainly catalyzed by CYP3A4 . Recent studies have reported, that CYP2C8 and CYP3A5 also hydroxylate AS to a minor extent [50, 52].
Furthermore, AS is transported into the cell via organic anion transport polypeptides (OATP), and recent studies on recombinant systems showed, that OATP1B1 and OATP2B1 contribute to the AS import [53, 54], which are both expressed in the human liver [55, 56]
OATP1B3 is supposed to be also a main contributor to drug transport , since it shows high gene expression levels in liver , but its importance for AS has not been investigated kinetically so far.
OATP transporters have been reported to be bidirectional facilitated diffusion transporters, independent from ATP and Na+, K+ and H+, but with a possible involvement of reduced glutathione [58, 59]. However, previous investigations on transport mechanisms on rat hepatocytes, showed, that the intracellular concentrations of pitavastatin and other compounds are much higher than outside the cell [33, 34, 60]. Facilitated or passive diffusion do not allow a greater intracellular than extracellular concentration of the parent drug of interest, when the source is the initial extracellular concentration, because it is a concentration-gradient dependent mechanism. Therefore, the import mechanism should be rather considered as active mediated transport, which is not concentration-gradient dependent, rather than as the proposed facilitated diffusion process.
As shown with the recombinantly expressed transporters mentioned above , transport of the acidic metabolites, ASpOH and ASoOH, by OATP1B1 was similar to that of AS, and transport of the corresponding lactones was also mediated by this transporter, although at somewhat lower rates. We therefore assumed that the same OATP transporters are responsible for the import of AS and its hydroxylated and lactone metabolites into hepatocytes.
AS and its hydroxylated metabolites, ASpOH and ASoOH, are actively exported out of the hepatocytes into the bile by the ATP-dependent MDR1 transporter [61, 62]. In addition, acidic and lactone form of AS showed inhibitory effects in transport studies of substrates of MDR1 and MRP2 [63–65], pointing to the competitive transport mechanism of these substrates at this proteins. Further, the transporters MRP1, MRP3 and MRP6 are also reported to be responsible for the transport of organic compounds including AS from inside the hepatocytes into the plasma [56, 66].
Passive diffusion might play also an important role in the transfer of AS, ASL and the corresponding metabolites, ASpOH and ASoOH, ASLpOH and ASLoOH, respectively. Since the acidic forms of AS are rather hydrophilic and the lactone forms of AS are rather lipophilic, it can be assumed that passive diffusion plays a more important role for the lactone forms, and the transporter mediated active transport plays a more important role for the acidic forms, as reported earlier for statins .
Finally, lipophilic drugs have a high affinity to bind non-specifically to proteins, and previous studies concentrated on the modeling of drug binding in the intracellular and the extracellular space as well as on the surface of the cells [60, 68, 69].
where the change in extracellular, intracellular or unspecific bound metabolite concentration c j in the extra - or intracellular compartment with V comp is effected by the conversion or production of contributing chemical or enzymatic reactions or by transport steps r ij , respectively. The extracellular volume, , equals to the volume of the media used. The intracellular volume, , equals to the total volume of all cells used, and is determined by multiplying the cell number by the volume of a single hepatocyte, estimated to be 14.1 pL by the approximation of a spherical shape with a diameter of 30 μm .
Appropriate reaction kinetics r ij are modeled for the CYP3A4 hydroxylation, the UGT1A3 lactonization, the chemical and enzymatic lactone hydrolysis and intracellular unspecific binding to macromolecules.
(see Additional file 1 - Derivation of Atorvastatin kinetics at CYP3A4).
which describes the ratio between the intracellular free concentration to the sum of intracellular free and bound concentration, and , in equilibrium (index eq) (see Additional file 2 - Derivation of kinetics of unspecific protein binding). However, the intracellular free and bound concentrations in equilibrium are not measurable; therefore, the fraction unbound fu j is set as a parameter to be estimated in the parameter optimization procedure.
is driven by the concentration difference between outside and inside the cell, , over the lipid-membrane with thickness d, through all cells with the total surface area A cells , and controlled by the diffusion coefficient D j and is comprised as the permeability coefficient P j .
Optimization procedure for estimation of model parameters
where the deviation of calculated and measured concentrations divided by the measurement standard deviation s j , squared and summed over all metabolites J and all time points N, has to reach a minimum. Additional optimization constraints are fu AS > fu ASL , P ASL > P AS , P AS > P ASOH and P ASL > P ASLOH , because the lactones have a higher lipophilicity than the acids and the metabolites are supposed to be more hydrophilic than the corresponding parent lactone or acid drug.
The integration of the differential equations (1) using the reaction kinetics in equations (2) to (9) was performed by the differential algebraic equation solver LIMEX (Konrad-Zuse-Zentrum für Informationstechnik, Berlin) .
Relative abundance approach for prediction of r max -parameters
The maximal velocities of the respective enzyme e, here CYP3A4 or UGT1A3, in the conversion to the product P j in the liver of interest li is estimated from the respective maximal rate and the enzyme concentration in the reference liver and the enzyme concentration in the liver of interest li.
The mathematical model of AS metabolism was coded in FORTRAN language and linked to the numerical integrator LIMEX, also written in FORTRAN. After compilation to the executable program, optimization was started by the call of JavaEva. The mathematical model is supplemented as SBML-file for review purpose.
Since the calibration and quality samples were prepared in the same media as the experimental metabolite samples and because it can be assumed that the intracellular protein concentration is much higher compared to the outside of the cells, the unspecific protein binding was only considered for the intracellular space.Regarding the unspecific protein binding, it can be assumed that the intracellular protein concentration is much higher compared to the outside of the cells. This assumption is based on the estimation of the ratio of intracellular protein to extracellular media protein concentration. From the total cell protein measurement and the determination of total cell volume a total intracellular protein concentration of about 30 g/l can be estimated. The media includes as sole protein component 0.1% (v/v) albumin, corresponding 1 g/l. Therefore, this assumption is justified.
Because our hepatocyte culture model does not allow to distinguish experimentally import and export, single irreversible, actively mediated transport steps for both directions, as well as passive diffusion steps were considered for each compound, respectively, similar to mechanistic transport models of other studies [33, 34]. Only in the case of AS different transport steps for OATP1B1 and OATP2B1 were implemented in the model, because specific KMs had been determined in previous studies [53, 54].
Model verification was performed by quantitative measurements of AS and all metabolites in the extra- and intracellular space during time-series experiments, performed first on a single batch of primary hepatocytes from a single individual 1. Special emphasis was given to the issue of parameter sensitivity and correlation between parameters to improve the quality of the model.
Time series/stimulus-response measurements on primary human hepatocytes
Recovery of atorvastatin metabolites in the time-series experiment on primary human hepatocytes of Individual 1
Parameters which were fixed in the optimization procedure to literature values
Analysis of the predicted concentration-time-profiles
Accordingly, the extracellular concentrations of the acidic metabolites are higher than that of the lactone metabolites. The ratio between extracellular AUC 0-600 min of the acidic form to that of the lactone form equals 54.3 in case of the para-hydroxy-metabolites and 70.8 in the case of the ortho-hydroxy-metabolites.
Further, the results show that the components have higher concentrations in the intracellular space than outside the cell. The ratio of intracellular AUC 0-600 min to extracellular AUC 0-600 min equals minimally 4.5 in the case of ASoOH and maximally 38.2 in the case of ASLpOH. Similarly, the ratio of intracellular c max to extracellular c max equals minimally 2.5 in the case of ASoOH and maximally 34.5 in the case of ASLpOH.
Simultaneous model verification on different individual hepatocyte donors
The process of model verification so far has been applied on a single experiment on primary human hepatocytes of individual 1. In the next step it has to be proven, that the model is also capable to describe different individual metabolic profiles, especially being further able to reflect the inter-individual parameter variability, not only in the parameters r max of the phase I and II reactions, but also in the transporters. Therefore, the model verification is performed based on AS biotransformation data on primary hepatocytes from three different individuals simultaneously.
Verified parameters of CYP3A4 and UGT1A3 in individual 1
rel. Error [%]
Protein concentrations of CYP3A4 and UGT1A3 in primary human hepatocytes
CYP3A4 [pmol ml-1]
± 107 (n = 2)
± 120 (n = 4)
± 19 (n = 2)
However, the analysis of parameter sensitivity and identifiability (see Additional file 4 - Analysis of parameter sensitivity and following model reduction procedure) showed that the first order kinetics of OATP1B1 mediated import is favored over the zero-order kinetics of OATP2B1 import of AS, and that the first order kinetics are hard to distinguish from first order passive diffusion mechanisms in this evaluation system. Thus, in the following, mechanisms of active transport and passive diffusion are lumped, resulting in the apparent transport rate for import,
The simultaneous model verification was performed based on the stimulus response data obtained from primary human hepatocytes of individual 1 (see Additional file 3 - Atorvastatin metabolite concentrations from the time-series experiment on primary human hepatocytes of individual 1), individual 2 (see Additional file 5 - Atorvastatin metabolite concentrations from the time-series experiment on primary human hepatocytes of individual 2) and individual 3 (see Additional file 6 - Atorvastatin metabolite concentrations from the time-series experiment on primary human hepatocytes of individual 3), respectively.
Parameter Variability in the simultaneous model verification on individual atorvastatin metabolism data.
The mathematical model of AS metabolism in human hepatocytes of individual 1 is supplemented as SBML-file (see Additional file 7 - Model of atorvastatin metabolism in primary human hepatocytes of individual 1, and BioModels database).
Dynamic analysis of inter-individual CYP3A4 and UGT1A3 expression level variability
Probability density functions fitted to inter-individual variability distributions
Probability density function
rel. s.d. [%]
AUC [pmol ml -1 *min]
c max [pmol ml -1 ]
t(c max ) [min]
Further, except for the AUC of AS, the probability density functions show a very narrow shape, regarding the relative standard deviation, when comparing to the sample standard deviations of the underlying distribution of CYP3A4 and UGT1A3, respectively. The probability density functions fitted to CYP3A4 and UGT1A3 distributions have a relative standard deviation of 259% and 137%, respectively, whereas the relative standard deviations of the probability density functions of AUC, cmax and t(cmax) are lower than 50%, except for the probability density function of AUC of intracellular AS, which equals 123%.
The deterministic modeling of drug metabolism has a major advantage compared to traditional pharmacokinetic models. The distinction between metabolism and elimination inside the hepatocytes and the detailed description of the biotransformation network structure allows the observation of the reaction kinetics and the transport mechanisms involved. Our modeling considered the major acid and lactone metabolites in the extracellular and intracellular space as well as appropriate reaction kinetics and transport steps. An experimental limitation in primary hepatocytes concerns the lower limit of quantification of each metabolite. Therefore, a relatively high initial concentration of AS of about 10 μM had to be chosen in order to permit measurement of the described major metabolites. Interestingly, the intracellular concentration of the parent drug AS was higher than the extracellular concentration. This indicates, that either the OATP mediated import does rather follow an active uptake mechanism than the proposed facilitated diffusion mechanism [58, 59], or so far unknown transporters may be involved in the transport steps. By any means it justifies the chosen implementation of kinetics for the active mediated transport beside the passive diffusion mechanism. In contrast to concentrations determined in plasma in clinical studies [54, 79, 81], extracellular concentrations of the acidic metabolites were much higher compared to the lactones. A possible explanation of these discrepancies may be that the in-vitro investigation on isolated primary human hepatocytes was performed over rather short time intervals (hours), whereas analyses in humans usually cover longer periods (days). A second explanation could be the relatively high initial concentration of AS of about 10 μM used in this study, compared to plasma concentrations observed to be lower than 200 (pmol ml-1). Furthermore, we found that the recovery of metabolites decreases over the time. This confirms on the one hand the contribution of unspecific binding to macromolecules, most severely in the intracellular space, as observed previously , but on the other hand could also be contributed to a certain extent by the unspecific binding to the collagen layer or the plates , especially of highly lipophilic ASL and lactone metabolites. However, due to the washing procedure preliminary to the cell harvesting and disruption procedure, this effect could not be observed in the chosen experimental set-up.
The parameter identification was considered satisfactory, as the simulation profiles fitted well to the corresponding measured metabolite concentration data. But, it was questionable if the optimized parameters could be considered to be sensitive and identifiable. Therefore, a local parameter sensitivity and identifiability analysis based on the Fisher-Information-Matrix was performed. The results showed that the full model of AS metabolism is not identifiable. Consequently a model reduction procedure was set-up and could be applied successfully, indicating that the parameter identification difficulties are caused by non-identifiable transporter steps, displayed by low parameter sensitivities and high parameter errors and correlations, which were then reduced in the model. However, this outcome does not necessarily mean that the non-identifiable transport steps are not present or not used in human hepatocytes, but rather implies, that they cannot be distinguished from the remaining transport steps in the model verification. Thus, the remaining transport steps in the model capture the probable superimposed contribution of several transport mechanisms in-vivo.
Unfortunately, the local identifiability of the final model version reveals some uncertainties caused by remaining high correlations present in the transport steps, as well as in the intracellular reaction network. An additional problem attributed to the modeling and parameter optimization is related to the fact that several parameters have lumped characteristics, because they are used for more than one compound, like the fraction unbound factor, which is set to be the same for all acidic or lactone AS compounds, respectively. A possible solution would be to set individual parameters for each compound. However, then the parameter identifiability difficulties would be even more severe. This is due to the fact, that the experimental observation on primary human hepatocytes is constrained strongly on several limitations. For example, the range of initial concentrations is strongly limited to the quantification of metabolites of interest. Further, the number of data points is strongly limited to the available cell number of primary hepatocytes, isolated from surgery removal. Finally, also the individual character of human cells due to individual genetic and medical background precludes an exact reproduction of experiments and the reproducibility of experimental results. The remaining parameter uncertainty seems to be crucial for the prediction of the population probability on the first sight. Actually, this is not the case. Since the parameter errors and the correlations indicate which parameter changes in what extent do not influence the computed time courses, the variability in the respective parameter error range would not influence the probability distributions. In general, the question if parameter errors and insensitivities are sufficiently small can only be answered when knowing the requirements of the pharmacological application as drug, which was not given in this study.
The simultaneous model verification based on primary human hepatocytes from different individuals illustrates the individual character of drug metabolism in the liver. Further, it indicates the inter-individual variability of rate parameters not only of the phase I and II enzymes, but also of the transport enzymes. In case of patients with type 2 diabetes, AS metabolism is probably influenced strongly by beta-oxidation and further so far unknown effects. Therefore, the individual model verification might also be used to reveal undesired pharmacokinetic effects. However, this analysis tool should be checked carefully on other drug systems in the future, too.
The individual nature of the AS metabolism was investigated in this study in the domain of inter-individual variability of CYP3A4 and UGT1A3 protein expression levels in human hepatocytes, by performing dynamic analysis on the verified model, individualized by implementation of a comprehensive set of protein data from a liver bank. The results show, that the inter-individual variability strongly affects the biotransformation behavior and therefore reveals the individual character of AS metabolism. Consequently, this individuality in the pharmacokinetics of AS also points out the individual character of pharmacodynamics at the drug target, namely the HMGCoA-reductase in human hepatocytes.
However, this subject-variability can also be expected to be present in the transport protein expression, as previously shown for OATP-C . Therefore, this variability should be taken into account in the future by implementing corresponding population expression data in the dynamic analysis. Another source of variation is the well-known polymorphism in CYP- and UGT- enzymes and likely transport proteins, which very probably causes inter-individual variations of the catalytic activity and the substrate affinity K M . Thus, further efforts should also consider this individual difference, leading to the improvement of the model prediction.
To resolve the contributing transport mechanisms in more detail, additional information should be implemented from transport investigations on recombinant systems, as described previously [72, 83], which enable the differentiated identification of both basolateral and apical transporters of AS and the corresponding transport kinetics. Further, also the estimation of unspecific drug protein binding could be improved in the future by using radiolabeled compounds in the experiments and modeling approaches as described previously [60, 69].
We believe that the results of our simulations provide strong arguments for rigorous dynamic modeling of drug biotransformation at the cellular level embedded in a systems biology approach. By resolving the detailed metabolic network structure with metabolites and catalyzing enzymes, we investigated the dynamic variation of atorvastatin metabolism affected by the inter-individual variability of expression levels of phase I and phase II enzymes.
In contrast to experimental investigations on recombinant systems or tissue fractions of hepatocytes, like microsomes, the investigation on primary human hepatocytes enabled the holistic and most realistic in-vitro observation of drug biotransformation, because it is possible to observe the coupled contribution of metabolism and transport to the entire processes. De novo of this study, we identified intracellular concentration profiles of atorvastatin metabolites in primary human hepatocytes in a time-series approach.
Such an approach is essential for integration of further-reaching issues, such as drug-drug interactions, impact of regulation networks linked to nuclear receptors and particularly to quantitatively account for subject-variability. The integration of this variability caused by genetic or environmental variations is crucial for predictive pharmacokinetic modeling.
Such a rigorous modeling approach critically depends upon a tight link between experimental observations and model design, simulation and verification. While the results are promising, some limitations in the parameter identification were still encountered. In the long term, these open problems can only be solved by stronger links to other research areas, such as pharmacogenetics, characterization of transporters, etc. On the whole, our contention is that the problem of parameter identifiability is an indispensable ingredient of model verification. Systematic investigations - if possible linked to optimal experimental design - can greatly strengthen the credibility of the models.
However, we present a model that goes much further. The domain of application does not remain the system behavior for which it has been elaborated. The model provides the possibility to link further modules such as gene regulation, drug target metabolism and present the important links to be implemented into the PBPK environment. Finally, the model structure used in this study should be considered as a module to be integrated into the framework of multi-scale whole body modeling and simulations necessary to tackle the drug disposition in patient populations.
List of abbreviations
hydroxy-atorvastatin acids (para- and ortho-)
hydroxy-atorvastatin lactones (para- and ortho-)
beta-oxidation of atorvastatin acids
- c :
index: intracellular (cytosol)
- calc :
- CR :
index: chemical reaction of hydrolysis of lactones
cytochrome P450 monooxygenase
- Den :
- e :
- eq :
- ex :
- fu :
- i :
- im :
- k :
index: parameter: rate constant
- K M :
- l :
- m :
index: extracellular (medium)
multidrug resistance protein
multidrug resistance-related protein
organic anion transport protein
maximal reaction rate
We thank Tanja Saussele and Ute Hofmann for initial help with analytical method setup, Bettina Serschnitzki and Elmar Langenfeld for support in AQUA method development and mass spectrometric analyses, and Michel Eichelbaum for helpful discussions. This work was funded by the HepatoSys network project of the German Federal Ministry of Education and Science (BMBF grants: 0313080F to JB, GV and MR, 0313080I to UMZ, 0313080J to AS and KM, 0313081B to AKN, 0313081D to TSW and WET).
- Bugrim A, Nikolskaya T, Nikolsky Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discovery Today. 2004, 9: 127-135. 10.1016/S1359-6446(03)02971-4View ArticlePubMedGoogle Scholar
- van de Waterbeemd H, Gifford E: ADMET in silico modelling: Towards prediction paradise?. Nature Reviews Drug Discovery. 2003, 2: 192-204. 10.1038/nrd1032View ArticlePubMedGoogle Scholar
- Kramer JA, Sagartz JE, Morris DL: The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007, 6: 636-649. 10.1038/nrd2378View ArticlePubMedGoogle Scholar
- Huisinga W, Telgmann R, Wulkow M: The virtual laboratory approach to pharmacokinetics: design principles and concepts. Drug Discovery Today. 2006, 11: 800-805. 10.1016/j.drudis.2006.07.001View ArticlePubMedGoogle Scholar
- Kitano H: Systems biology: a brief overview. Science. 2002, 295: 1662-1664. 10.1126/science.1069492View ArticlePubMedGoogle Scholar
- Spivey A: Systems biology - The big picture. Environmental Health Perspectives. 2004, 112: A938-A943.PubMed CentralView ArticlePubMedGoogle Scholar
- Andersson TB, Bredberg E, Ericsson H, Sjoberg H: An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metabolism and Disposition. 2004, 32: 715-721. 10.1124/dmd.32.7.715View ArticlePubMedGoogle Scholar
- Clarke SE, Jeffrey P: Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica. 2001, 31: 591-598. 10.1080/00498250110057350View ArticlePubMedGoogle Scholar
- Lin JH: Sense and nonsense in the prediction of drug-drug interactions. Current Drug Metabolism. 2000, 1: 305-331. 10.2174/1389200003338947View ArticlePubMedGoogle Scholar
- de Groot MJ, Ekins S: Pharmacophore modeling of cytochromes P450. Advanced Drug Delivery Reviews. 2002, 54: 367-383. 10.1016/S0169-409X(02)00009-1View ArticlePubMedGoogle Scholar
- Gasteiger J, Reitz M, Han YQ, Sacher O: Analyzing biochemical pathways using neural networks and genetic algorithms. Australian Journal of Chemistry. 2006, 59: 854-858. 10.1071/CH06140.View ArticleGoogle Scholar
- Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, Ivashchenko AA, Nikolskaya T: Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. Journal of Medicinal Chemistry. 2003, 46: 3631-3643. 10.1021/jm030102aView ArticlePubMedGoogle Scholar
- Lewis DFV, Ioannides C, Parke DV: An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. Drug Metabolism Reviews. 1998, 30: 709-737. 10.3109/03602539808996328View ArticlePubMedGoogle Scholar
- Lewis DFV, Ioannides C, Parke DV: Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 1998, 412: 41-54. 10.1016/S1383-5718(97)00145-9View ArticlePubMedGoogle Scholar
- Terfloth L, Bienfait B, Gasteiger J: Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. Journal of Chemical Information and Modeling. 2007, 47: 1688-1701. 10.1021/ci700010tView ArticlePubMedGoogle Scholar
- Zhang EY, Phelps MA, Cheng C, Ekins S, Swaan PW: Modeling of active transport systems. Advanced Drug Delivery Reviews. 2002, 54: 329-354. 10.1016/S0169-409X(02)00007-8View ArticlePubMedGoogle Scholar
- Ekins S, Erickson JA: A pharmacophore for human pregnane X receptor ligands. Drug Metabolism and Disposition. 2002, 30: 96-99. 10.1124/dmd.30.1.96View ArticlePubMedGoogle Scholar
- Ekins S, Mirny L, Schuetz EG: A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXR alpha, and LXR beta. Pharmaceutical Research. 2002, 19: 1788-1800. 10.1023/A:1021429105173View ArticlePubMedGoogle Scholar
- Hou TJ, Wang JM, Li YY: ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. Journal of Chemical Information and Modeling. 2007, 47: 2408-2415. 10.1021/ci7002076View ArticlePubMedGoogle Scholar
- Hou TJ, Wang JM, Zhang W, Xu XJ: ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?. Journal of Chemical Information and Modeling. 2007, 47: 460-463. 10.1021/ci6003515View ArticlePubMedGoogle Scholar
- Hou TJ, Zhang W, Xia K, Qiao XB, Xu XJ: ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. Journal of Chemical Information and Computer Sciences. 2004, 44: 1585-1600.PubMedGoogle Scholar
- Leonard JT, Roy K: On selection of training and test sets for the development of predictive QSAR models. Qsar & Combinatorial Science. 2006, 25: 235-251. 10.1002/qsar.200510161View ArticleGoogle Scholar
- Rostami-Hodjegan A, Tucker GT: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery. 2007, 6: 140-148. 10.1038/nrd2173View ArticlePubMedGoogle Scholar
- Andersen ME: Development of Physiologically-Based Pharmacokinetic and Physiologically-Based Pharmacodynamic Models for Applications in Toxicology and Risk Assessment. Toxicology Letters. 1995, 79: 35-44. 10.1016/0378-4274(95)03355-OView ArticlePubMedGoogle Scholar
- Gerlowski LE, Jain RK: Physiologically Based Pharmacokinetic Modeling - Principles and Applications. Journal of Pharmaceutical Sciences. 1983, 72: 1103-1127. 10.1002/jps.2600721003View ArticlePubMedGoogle Scholar
- Reddy M, Yang RS, Andersen ME, Clewell I, H J: Phyiologically Based Pharmacokinetic Modelling. 2005, John Wiley & Sons,View ArticleGoogle Scholar
- Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K: Approaches for applications of physiologically based pharmacokinetic models in risk assessment. Journal of Toxicology and Environmental Health-Part B-Critical Reviews. 2008, 11: 519-547. 10.1080/10937400701724337.View ArticleGoogle Scholar
- Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W: PK-Sim®: a physiologically based pharmacokinetic 'whole-body' model. Biosilico. 2003, 1:Google Scholar
- Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW: Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Current Topics in Medicinal Chemistry. 2005, 5: 1033-1038. 10.2174/156802605774297038View ArticlePubMedGoogle Scholar
- Hop CECA, Cole MJ, Davidson RE, Duignan DB, Federico J, Janiszewski JS, Jenkins K, Krueger S, Lebowitz R, Liston TE, Mitchell W, Snyder M, Steyn SJ, Soglia JR, Taylor C, Troutman MD, Umland J, West M, Whalen KM, Zelesky V, Zhao SX: High Throughput ADME Screening: Practical Considerations, Impact on the Portfolio and Enabler of In Silico ADME Models. Current Drug Metabolism. 2008, 9: 847-853. 10.2174/138920008786485092View ArticlePubMedGoogle Scholar
- Singh SS: Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Current Drug Metabolism. 2006, 7: 165-182. 10.2174/138920006775541552View ArticlePubMedGoogle Scholar
- Nestorov I: Whole-body physiologically based pharmacokinetic models. Expert Opinion on Drug Metabolism & Toxicology. 2007, 3: 235-249. 10.1517/17425255.3.2.235View ArticleGoogle Scholar
- Baker M, Parton T: Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica. 2007, 37: 1110-1134. 10.1080/00498250701658296View ArticlePubMedGoogle Scholar
- Poirier A, Lave T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C: Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model. Drug Metabolism and Disposition. 2008, 36: 2434-2444. 10.1124/dmd.108.020750View ArticlePubMedGoogle Scholar
- Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ: Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metabolism and Disposition. 2008, 36: 1365-1374. 10.1124/dmd.107.019455View ArticlePubMedGoogle Scholar
- Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, Jauch KW: Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank. 2003, 4: 49-56. 10.1023/A:1026392429112View ArticlePubMedGoogle Scholar
- Nussler AK, Nussler NC, Merk V, Brulport M, Schormann W, Yao P, Hengstler JG: The Holy grail of hepatocyte culturing and therapeutic use. Strategies in Regenerative Medicine. Edited by: Santin M. 2008, New York: Springer,Google Scholar
- Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2009, 87: 65-73.View ArticlePubMedGoogle Scholar
- Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003, 38: 978-988.View ArticlePubMedGoogle Scholar
- Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K: Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics. 2009, 9: 2313-2323. 10.1002/pmic.200800680View ArticlePubMedGoogle Scholar
- Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM: Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007, 35: 1315-1324. 10.1124/dmd.107.015230View ArticlePubMedGoogle Scholar
- Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002, 30: 505-512. 10.1124/dmd.30.5.505View ArticlePubMedGoogle Scholar
- Kearney AS, Crawford LF, Mehta SC, Radebaugh GW: The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res. 1993, 10: 1461-1465. 10.1023/A:1018923325359View ArticlePubMedGoogle Scholar
- Aviram M, Rosenblat M: Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008, 477: 259-276. 10.1007/978-1-60327-517-0_20View ArticlePubMedGoogle Scholar
- Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000, 275: 33435-33442. 10.1074/jbc.M004543200View ArticlePubMedGoogle Scholar
- Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005, 46: 1239-1247. 10.1194/jlr.M400511-JLR200View ArticlePubMedGoogle Scholar
- Gouedard C, Koum-Besson N, Barouki R, Morel Y: Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003, 63: 945-956. 10.1124/mol.63.4.945View ArticlePubMedGoogle Scholar
- Khersonsky O, Tawfik DS: Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005, 44: 6371-6382. 10.1021/bi047440dView ArticlePubMedGoogle Scholar
- Christians U, Jacobsen W, Floren LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol Ther. 1998, 80: 1-34. 10.1016/S0163-7258(98)00016-3View ArticlePubMedGoogle Scholar
- Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000, 28: 1369-1378.PubMedGoogle Scholar
- Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T: Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004, 34: 961-971. 10.1080/00498250400015319View ArticlePubMedGoogle Scholar
- Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG: Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica. 2008, 38: 1240-1251. 10.1080/00498250802334391View ArticlePubMedGoogle Scholar
- Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clinical Pharmacology & Therapeutics. 2006, 80: 607-620. 10.1016/j.clpt.2006.09.010View ArticleGoogle Scholar
- Lau YY, Huang Y, Frassetto L, Benet LZ: effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007, 81: 194-204. 10.1038/sj.clpt.6100038View ArticlePubMedGoogle Scholar
- Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005, 20: 452-477. 10.2133/dmpk.20.452View ArticlePubMedGoogle Scholar
- Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010, 106: 297-306. 10.1161/CIRCRESAHA.109.203596View ArticlePubMedGoogle Scholar
- Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition. 2007, 35: 1333-1340. 10.1124/dmd.107.014902View ArticlePubMedGoogle Scholar
- Li L, Lee TK, Meier PJ, Ballatori N: Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem. 1998, 273: 16184-16191. 10.1074/jbc.273.26.16184View ArticlePubMedGoogle Scholar
- Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N: Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol. 2007, 293: G271-278. 10.1152/ajpgi.00075.2007View ArticlePubMedGoogle Scholar
- Kilford PJ, Gertz M, Houston JB, Galetin A: Hepatocellular binding of drugs: Correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metabolism and Disposition. 2008, 36: 1194-1197. 10.1124/dmd.108.020834View ArticlePubMedGoogle Scholar
- Bogman K, Peyer AK, Torok M, Kusters E, Drewe J: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001, 132: 1183-1192. 10.1038/sj.bjp.0703920PubMed CentralView ArticlePubMedGoogle Scholar
- Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000, 40: 91-98. 10.1177/00912700022008612View ArticlePubMedGoogle Scholar
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005, 33: 537-546. 10.1124/dmd.104.002477View ArticlePubMedGoogle Scholar
- Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T: Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004, 21: 1686-1691.View ArticlePubMedGoogle Scholar
- Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K: Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharmaceutical Research. 2006, 23: 506-512. 10.1007/s11095-005-9371-5View ArticlePubMedGoogle Scholar
- Chandra P, Brouwer KLR: The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research. 2004, 21: 719-735.View ArticlePubMedGoogle Scholar
- Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences. 1998, 19: 26-37. 10.1016/S0165-6147(97)01147-4View ArticlePubMedGoogle Scholar
- Austin RP, Barton P, Mohmed S, Riley RJ: The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos. 2005, 33: 419-425.View ArticlePubMedGoogle Scholar
- Hallifax D, Houston JB: Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos. 2006, 34: 1829-1836. 10.1124/dmd.106.010413View ArticlePubMedGoogle Scholar
- Schwartlander R, Schmid J, Brandenburg B, Katenz E, Wolfgang F, Vondran R, Pless G, Cheng XD, Pascher A, Neuhaus P, Sauer IM: Continuously microscopically observed and process-controlled cell culture within the SlideReactor: Proof of a new concept for cell characterization. Tissue Engineering. 2007, 13: 187-196. 10.1089/ten.2006.0071View ArticlePubMedGoogle Scholar
- Toutain PL, Bousquet-Melou A: Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002, 25: 460-463. 10.1046/j.1365-2885.2002.00442.xView ArticlePubMedGoogle Scholar
- Bartholome K, Rius M, Letschert K, Keller D, Timmer J, Keppler D: Data-based mathematical modeling of vectorial transport across double-transfected polarized cells. Drug Metab Dispos. 2007, 35: 1476-1481. 10.1124/dmd.107.015636View ArticlePubMedGoogle Scholar
- Poland J, Zell A: Main Vector Adaptation: A CMA Variant with Linear Time and Space Complexity. Proceedings of the Genetic and Evolutionary Computation Conference (GECCO-2001); Washington, D.C., USA. 2001, 312-317.Google Scholar
- Deuflhard P, Hairer E, Zugck J: One-Step and Extrapolation Methods for Differential-Algebraic Systems. Numerische Mathematik. 1987, 51: 501-516. 10.1007/BF01400352.View ArticleGoogle Scholar
- Prueksaritanont T, Ma B, Fang X, Subramanian R, Yu J, Lin JH: beta-Oxidation of simvastatin in mouse liver preparations. Drug Metab Dispos. 2001, 29: 1251-1255.PubMedGoogle Scholar
- Deng WJ, Nie S, Dai J, Wu JR, Zeng R: Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics. 2010, 9: 100-116. 10.1074/mcp.M900020-MCP200PubMed CentralView ArticlePubMedGoogle Scholar
- Motawi TM, Hashem RM, Rashed LA, El-Razek SM: Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats. J Pharm Pharmacol. 2009, 61: 1339-1346.View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3View ArticlePubMedGoogle Scholar
- Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH: Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003, 18: 967-976. 10.1093/ndt/gfg048View ArticlePubMedGoogle Scholar
- Launay-Vacher V, Izzedine H, Deray G: Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005, 101: 9-17. 10.1016/j.ijcard.2004.04.005View ArticlePubMedGoogle Scholar
- Kantola T, Kivisto KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998, 64: 58-65. 10.1016/S0009-9236(98)90023-6View ArticlePubMedGoogle Scholar
- Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001, 276: 35669-35675. 10.1074/jbc.M103792200View ArticlePubMedGoogle Scholar
- Cui YH, Konig J, Keppler D: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Molecular Pharmacology. 2001, 60: 934-943.PubMedGoogle Scholar